Iroko Pharmaceuticals is a global specialty pharmaceutical company focused on developing and commercializing innovative treatment options for responsible pain management.

  • Through a dynamic, collaborative approach—including the use of novel and proprietary technologies—Iroko develops and commercializes products that help patients manage their pain responsibly
  • Iroko’s goal is to deliver value to patients, health care professionals, and other stakeholders

Iroko’s commitment to responsible pain management

For Iroko Pharmaceuticals, the phrase “responsible pain management” refers to therapeutic approaches to managing pain that carefully consider the impact potential adverse events can have on the health and well-being of patients. Iroko believes the term can and should serve as an effective call to action for the use of all pain medicines, including NSAIDs. In fact, decades of evidence demonstrate that the higher the NSAID dose, the higher the risk of certain serious adverse events.1-6

 

In this context, Iroko believes responsible pain management should involve:

  • Developing and delivering medicines that can effectively relieve pain
  • Carefully considering the risks and consequences that may result from patients taking such medicines
  • Engineering low-dose pain management options that address the dose-related risks of NSAIDs
  • Promoting awareness among health care professionals of the risks and consequences of pain management options, while also encouraging consideration of recommendations by regulatory and professional medical organizations
  • Understanding the larger implications of “responsibility,” not just in relation to patients, but in relation to communities and the environment at large

The story behind Iroko’s name

Iroko Pharmaceuticals is named for the majestic West African Iroko tree, whose deep roots and lush foliage symbolize stability, value, and continuous renewal.

  • The leaves of the Iroko tree represent our products, which reinvent and renew trusted approaches to managing pain
  • The trunk of the Iroko tree represents Iroko’s network of employees and partners
  • The roots of the Iroko tree represent the foundation of all Iroko does: Improving the lives of patients across the world

Iroko Pharmaceuticals Announces Leadership Changes

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of SoluMatrix™ technology based nonsteroidal anti-inflammatory drugs (NSAIDs), announces that Osagie Imasogie, Founder, Chairman of the Board and former CEO and President, stepped down as Board Chairman as of January 2017. Mr. Imasogie continues to serve on Iroko’s Board of Directors.

Louis Vollmer, President and Chief Executive Officer, has also relinquished his positions at the company.

Iroko Pharmaceuticals markets three FDA-approved low-dose SoluMatrix® NSAIDs VIVLODEX®, TIVORBEX® and ZORVOLEX®, as well as INDOCIN® (indomethacin) oral suspension and suppositories as alternatives to tablets or capsules.

Iroko will continue to provide healthcare professionals and patients access to products that are focused on providing choice of effective pain therapies at an affordable price. Healthcare professionals and patients can access product information and updates at iroko.com.

Media and business development inquiries may also be submitted at iroko.com.

For Important Safety Information regarding our products, please see our Products page.

SoluMatrix® is a trademark of iCeutica Pty Ltd and is licensed to Iroko.

References:

  1. Castellsague J, Riera-Guardia N, Calingaert B, et al; on behalf of the investigators of the Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS Project). Drug Saf. 2012;35(12):1127-1146.
  2. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):1-18.
  3. Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005;45(3):531-539.
  4. García Rodríguez LA, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001;12(5):570-576.
  5. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomized trials. Lancet. 2013;382:769-779.
  6. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52(20):1628-1636.